In yesterday’s Wall Street session, Immutep Limited (NASDAQ:IMMP) shares traded at $2.45, up 6.52% from the previous session.
As of this writing, 7 analysts cover Immutep Limited (NASDAQ:IMMP). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $19.53 and a low of $6.03, we find $8.31. Given the previous closing price of $2.30, this indicates a potential upside of 261.3 percent. IMMP stock price is now 41.54% away from the 50-day moving average and 30.00% away from the 200-day moving average. The market capitalization of the company currently stands at $203.64M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
There are 0 analysts who have given it a hold rating, whereas 6 have given it a buy rating. Brokers who have rated the stock have averaged $9.80 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in IMMP stock. A new stake in Immutep Limited shares was purchased by XY CAPITAL LTD during the first quarter worth $34,000. In total, there are 29 active investors with 6.10% ownership of the company’s stock.
Wednesday morning saw Immutep Limited (NASDAQ: IMMP) opened at $2.5200. During the past 12 months, Immutep Limited has had a low of $1.47 and a high of $3.90. The fifty day moving average price for IMMP is $1.7452 and a two-hundred day moving average price translates $1.8858 for the stock.
The latest earnings results from Immutep Limited (NASDAQ: IMMP) was released for Dec, 2022. For the current quarter, analysts expect IMMP to generate $2.59M in revenue.
Immutep Limited(IMMP) Company Profile
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
Leave a Reply